Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 241 to 255 of 438 results for cardiovascular disease

  1. Seven digital platforms supporting at home cardiac rehab given conditional recommendations

    People with heart disease will be able to do their recovery sessions from home rather than travelling for rehabilitation appointments after our independent committee conditionally recommended 7 digital platforms for use in the NHS.

  2. Myocardial infarction: cardiac rehabilitation and prevention of further cardiovascular disease (CG172)

    This guideline has been updated and replaced by NICE guideline NG185.

  3. Interventional procedures advisory committee members

    Membership details, terms of reference, future meeting dates and past meeting minutes for our interventional procedures advisory committee.

  4. Cardiovascular disease: risk assessment and reduction, including lipid modification (CG181)

    This guideline has been updated and replaced by NICE guideline NG238.

  5. Percutaneous radiofrequency ablation for atrial fibrillation (IPG168)

    Evidence-based recommendations on percutaneous radiofrequency ablation for atrial fibrillation. This involves inserting a catheter into the heart that produces heat to damage the nerves in the area with the abnormal elecritcal impulses.

  6. Technology appraisal committee D members

    Find out more about NICE technology appraisals advisory committee D members

  7. Use of hearing aids and incidence of dementia:- In adults with hearing loss, does the use of hearing aids reduce the incidence of dementia?

    susceptibility, environmental factors or age-related factors such as cardiovascular disease. Hearing loss may cause dementia either...

  8. Percutaneous pulmonary valve implantation for right ventricular outflow tract dysfunction (IPG436)

    Evidence-based recommendations on percutaneous pulmonary valve implantation for right ventricular outflow tract dysfunction. This involves implanting a replacement valve with a wire mesh tube called a stent.

  9. Topotecan for the treatment of recurrent and stage IVB cervical cancer (TA183)

    Evidence-based recommendations on topotecan for treating recurrent and stage IVB cervical cancer in adults.

  10. Technology appraisal committee B members

    Find out more about the NICE technology appraisal advisory committee B members and their registered interests

  11. Cannabis-based medicinal products (NG144)

    This guideline covers prescribing of cannabis-based medicinal products for people with intractable nausea and vomiting, chronic pain, spasticity and severe treatment-resistant epilepsy.

  12. Pembrolizumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer (TA1017)

    Evidence-based recommendations on pembrolizumab (Keytruda) with chemotherapy before surgery (neoadjuvant) and then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer in adults

  13. Sebelipase alfa for treating Wolman disease (HST30)

    Evidence-based recommendations on sebelipase alfa (Kanuma) for long-term enzyme replacement therapy in Wolman disease (rapidly progressive lysosomal acid lipase deficiency) in people aged 2 years and under when treatment starts.

  14. Everolimus for preventing organ rejection in liver transplantation (TA348)

    Evidence-based recommendations on everolimus (Certican) for preventing organ rejection in adults having a liver transplant.

  15. Behaviour change: individual approaches (PH49)

    This guideline covers changing health-damaging behaviours among people aged 16 and over using interventions such as goals and planning, feedback and monitoring, and social support. It aims to help tackle a range of behaviours including alcohol misuse, poor eating patterns, lack of physical activity, unsafe sexual behaviour and smoking.